---
title: "BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295718009.md"
description: "The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-12T22:50:16.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295718009.md)
  - [en](https://longbridge.com/en/news/295718009.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295718009.md)
generator: "portal-rs"
---

# BIVI: Bezisterim phase II data show significant motor and non-motor benefits and slowed neurodegeneration

The SUNRISE-PD phase II trial of bezisterim in early Parkinson's showed significant improvements in both motor and non-motor symptoms, especially in patients with higher baseline inflammation. Biomarker data suggest slowed neurodegeneration, and the drug was well-tolerated, supporting a phase III trial with an enrichment strategy.

Based on 

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [BIVI.US](https://longbridge.com/en/quote/BIVI.US.md)
- [BIVIW.US](https://longbridge.com/en/quote/BIVIW.US.md)

## Related News & Research

- [BioVie seeks FDA end-of-Phase 2 meeting to advance bezisterim Phase 3 Parkinson’s trial design](https://longbridge.com/en/news/298310944.md)
- [BIVI: Bezisterim showed significant clinical and biomarker benefits in early Parkinson's, supporting Phase 3](https://longbridge.com/en/news/295701512.md)
- [IMUX: Pivotal phase III data for vidofludimus calcium in relapsing MS expected by year-end, targeting NDA in 2025](https://longbridge.com/en/news/298495158.md)
- [IMUX: Pivotal Phase 3 data for vidofludimus calcium in relapsing MS expected by end of 2026](https://longbridge.com/en/news/298485112.md)
- [Scientist Home Future Health reports clinical trial shows severe eczema symptoms decline with nutritional therapy](https://longbridge.com/en/news/298590055.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**